DALLAS, Jan. 11, 2010 (GLOBE NEWSWIRE) -- StockPreacher.com announces an investment report featuring Cyclacel Pharmaceuticals Inc. (Nasdaq:CYCC). The report includes financial and investment analysis, analyst consensus, and pertinent industry information you need to know to make an educated investment decision.
The full report is available at: http://www.stockpreacher.com/n/CYCC
Get our alerts BEFORE the rest of the market. Follow us on Twitter: http://twitter.com/StockPreacher
Cyclacel Pharmaceuticals Inc. (CYCC), a development-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel, mechanism-targeted drugs to treat human cancers and other serious disorders. CYCC's pipeline currently includes three clinical-stage compounds, sapacitabine (CYC682), seliciclib (CYC202) and CYC116. The Company, through its subsidiary, ALIGN Pharmaceuticals LLC, markets directly Xclair Cream for radiation dermatitis, as well as Numoisyn Liquid and Numoisyn Lozenges for xerostomia in the United States.
Message Board Search for CYCC: http://www.boardcentral.com/boards/CYCC
In the report, the analyst notes:
"On January 7, the Company announced the publication of peer-reviewed journal articles discussing and reviewing its drug candidate seliciclib (CYC202 or R-roscovitine). In an article published in Clinical Cancer Research, seliciclib was reportedly found to be effective in killing lung cancer cells through a novel apoptotic mechanism or induction of cancer cell suicide. According to Prof. David Glover Ph.D., CYCC's chief scientist, 'The publication sets out the body of evidence that seliciclib is a promising anti-cancer agent that promotes cancer cell death by down-regulation of key proteins, such as p53 and Mcl-1, associated with survival of cancer cells...'
"Operating in rapidly changing and highly competitive biotechnology and biopharmaceutical industries, CYCC seeks to develop and market drug candidates that will compete with other products and therapies that currently exist or are being developed. The Company has identified three key elements to its business strategy..."
To read the entire report visit: http://www.stockpreacher.com/n/CYCC
See what investors are saying about CYCC at penny stock forum.
StockPreacher.com is a small-cap research and investment commentary provider. StockPreacher.com strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on StockPreacher, please visit: http://www.stockpreacher.com
StockPreacher.com Disclosure
StockPreacher.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. StockPreacher.com is a Web site wholly-owned by BlueWave Advisors, LLC. Please read our report and visit our Web site, StockPreacher.com, for complete risks and disclosures.